Media Releases

Battlefords Union Hospital goes live with the Cobas 6000 Chemistry Analyzer

Saskatchewan, September 10, 2008

Battlefords Union Hospital goes live with the Cobas 6000 Chemistry Analyzer

Battlefords Union Hospital Laboratory announces the completion of the installation of a new analyzer that provides the latest technology to respond to physician requests for blood tests. This installation will have a very positive impact on the level of care provided to patients. The new piece of equipment, called the cobas 6000 analyzer series, was officially unveiled during a ribbon-cutting ceremony held September 10, 2008. All employees were invited to join the laboratory staff in celebrating their new system.

As the number of lab tests continues to increase, it becomes more important for the laboratory to upgrade its capability and improve efficiencies. The cobas 6000 analyzer series, which is manufactured by Roche Diagnostics, will consolidate the testing previously performed by three other units in the laboratory. The analyzer has a testing menu that covers the majority of the laboratory’s typical tests and has the capacity to grow as the volume of testing increases.

“We see so many benefits the cobas 6000 analyzer series brings to our laboratory,” said Pam Nyholt, Laboratory Supervisor. “Physicians and patients will see fast, reliable, and accurate results; the laboratory will become more efficient and productive; and the hospital will improve the quality of its patient care.” 

“We are extremely pleased to be working with Battlefords Union Hospital to showcase the latest technology in laboratory analyzers” said Christopher Parker, President and General Manager of Roche Diagnostics in Canada. “The cobas 6000 allows laboratories to greatly enhance their testing efficiency while at the same time delivering the highest quality patient results. It will provide the hospital laboratory the flexibility to quickly respond to future growth in testing requirements.”

Upgrading the laboratory was a tremendous task, however, according to Pam Nyholt, Laboratory Supervisor. The transition was fairly smooth and few people in the hospital noticed it was going on.  “Whenever you take on this type of project, you worry how it will affect the daily workload and if it will slow down the process,” said Pam Nyholt. “However, the entire process was almost painless thanks in part to Roche Diagnostics technical support, and the BUH team which included Maintenance, Information Technologies and Laboratory staff. The team kept everything moving on schedule without interfering with our normal day-to-day processes. It was much better than I thought it would be.”

The Regional Director of Laboratory Services, Elaine Blais, also sees good things ahead thanks to the cobas 6000 analyzer series.  “By upgrading our laboratory with Roche equipment, we can continue to enhance the practice of laboratory medicine for years to come,” she said. On behalf of laboratory services, physicians, and residents of the community; a heartfelt thank-you is extended to the BUH Foundation and the BATC Community Development Corporation for the funding assistance which created the opportunity for the laboratory to replace fourteen year old equipment with state of the art instrumentation.

- 30 -


About Battlefords Union Hospital
Battlefords Union Hospital is a 96-bed (including 22 mental health inpatient beds) acute care facility  defined by the province of Saskatchewan as a Regional Hospital.  Battlefords Union Hospital provide a range of services including 24 hour emergency care, laboratory and diagnostic imaging, and general medicine for adults and children, as well as basic specialty services including internal medicine, general surgery, obstetrics and gynaecology, and intensive care services.

For more information, please contact:
Elaine Blais
Regional Director of Laboratory Services
306-446-6596
elaine.blais@pnrha.ca

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion Swiss francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at www.roche.com and www.rochediagnostics.ca.

For more information, please contact:
Michèle Beaubien
Roche Diagnostics
(450) 686-5500
michele.beaubien@roche.com

Prev                                                           Back to list                                                       Next